- Home
- EOSE vs DNLI Comparison
EOSE vs DNLI Comparison
Compare EOSE & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOSE
- DNLI
- Stock Information
- Founded
- EOSE 2008
- DNLI 2013
- Country
- EOSE United States
- DNLI United States
- Employees
- EOSE N/A
- DNLI N/A
- Industry
- EOSE Industrial Machinery/Components
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EOSE Miscellaneous
- DNLI Health Care
- Exchange
- EOSE Nasdaq
- DNLI Nasdaq
- Market Cap
- EOSE 2.3B
- DNLI 2.1B
- IPO Year
- EOSE N/A
- DNLI 2017
- Fundamental
- Price
- EOSE $13.69
- DNLI $14.99
- Analyst Decision
- EOSE Buy
- DNLI Strong Buy
- Analyst Count
- EOSE 5
- DNLI 15
- Target Price
- EOSE $7.90
- DNLI $33.50
- AVG Volume (30 Days)
- EOSE 21.2M
- DNLI 2.1M
- Earning Date
- EOSE 11-04-2025
- DNLI 11-05-2025
- Dividend Yield
- EOSE N/A
- DNLI N/A
- EPS Growth
- EOSE N/A
- DNLI N/A
- EPS
- EOSE N/A
- DNLI N/A
- Revenue
- EOSE $33,800,000.00
- DNLI N/A
- Revenue This Year
- EOSE $857.58
- DNLI N/A
- Revenue Next Year
- EOSE $225.49
- DNLI $95,463.19
- P/E Ratio
- EOSE N/A
- DNLI N/A
- Revenue Growth
- EOSE 128.49
- DNLI N/A
- 52 Week Low
- EOSE $2.06
- DNLI $10.57
- 52 Week High
- EOSE $15.19
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- EOSE 84.84
- DNLI 57.22
- Support Level
- EOSE $9.78
- DNLI $12.58
- Resistance Level
- EOSE $15.18
- DNLI $15.75
- Average True Range (ATR)
- EOSE 1.00
- DNLI 0.65
- MACD
- EOSE 0.30
- DNLI 0.21
- Stochastic Oscillator
- EOSE 78.38
- DNLI 76.97
About EOSE Eos Energy Enterprises Inc.
Eos Energy Enterprises Inc designs develop, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial & industrial (C&I) applications. The solutions are used in the utility sector, the renewable energy sector, and the industrial sector. It's flagship product Eos Znyth is a stationary battery energy storage system.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.